Doxorubicin-loaded highly porous large PLGA microparticles as a sustained- release inhalation system for the treatment of metastatic lung cancer

Biomaterials

Volumn 33, Issue 22, 2012, Pages 5574-5583

  Kim, Insoo ^a   Byeon, Hyeong Jun ^a   Kim, Tae Hyung ^a   Lee, Eun Seong ^b   Oh, Kyung Taek ^c   Shin, Beom Soo ^d   Lee, Kang Choon ^a   Youn, Yu Seok ^a  

^a Sungkyunkwan University   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c Chung Ang University   (South Korea)

^d Catholic University of Daegu   (South Korea)

Author keywords

Doxorubicin; Inhalation; Lung cancer; Porous microparticles; Sustained release

Indexed keywords

DOXORUBICIN; INHALATION; LUNG CANCER; MICRO-PARTICLES; SUSTAINED-RELEASE;

AMMONIUM COMPOUNDS; BIOLOGICAL ORGANS; CONFOCAL MICROSCOPY; DERMATOLOGY; DISEASES; EMULSIFICATION; ENCAPSULATION; ONCOLOGY; PARTICLE SIZE ANALYSIS; SCANNING ELECTRON MICROSCOPY;

MAMMALS;

DOXORUBICIN; POLYGLACTIN;

AEROSOL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG EXPOSURE; EMULSION; IN VITRO STUDY; LUNG CANCER; LUNG PARENCHYMA; MALE; MELANOMA CELL; MOUSE; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; POROSITY; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; SUSTAINED RELEASE PREPARATION; TREATMENT RESPONSE;

ADMINISTRATION, INHALATION; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CAPSULES; DELAYED-ACTION PREPARATIONS; DOXORUBICIN; LACTIC ACID; LIPOSOMES; LUNG NEOPLASMS; MALE; MELANOMA; MICE; MICE, INBRED C57BL; POLYGLYCOLIC ACID; TREATMENT OUTCOME;

MUS;

EID: 84861225755     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.04.018     Document Type: Article

References (31)

1. Johnson D.H. Treatment strategies for metastatic non small-cell lung cancer. Clin Lung Cancer 1999, 1:34-41.
2. Carballo M., Maish M.S., Jaroszewski D.E., Holmes C.E. Video-assisted thoracic surgery (VATS) as a safe alternative for the resection of pulmonary metastases: a retrospective cohort study. J Cardiothorac Surg 2009, 4:13.
3. Goto H., Yano S., Zhang H., Matsumori Y., Ogawa H., Blakey D.C., et al. Activity of a new vascular targeting agent, ZD6126, in pulmonary metastases by human lung adenocarcinoma in nude mice. Cancer Res 2002, 62:3711-3715.
4. Tseng C.L., Su W.Y., Yen K.C., Yang K.C., Lin F.H. The use of biotinylated-EGF-modified gelatin nanoparticle carrier to enhance cisplatin accumulation in cancerous lungs via inhalation. Biomaterials 2009, 30:3476-3485.
5. Burris H.A. Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs. Oncogene 2009, 28:S4-13.
6. Wauthoz N., Deleuze P., Hecq J., Roland I., Saussez S., Adanja I., et al. In vivo assessment of temozolomide local delivery for lung cancer inhalation therapy. Eur J Pharm Sci 2010, 39:402-411.
7. Garbuzenko O.B., Saad M., Pozharov V.P., Reuhl K.R., Mainelis G., Minko T. Inhibition of lung tumor growth by complex pulmonary delivery of drugs with oligonucleotides as suppressors of cellular resistance. Proc Natl Acad Sci USA 2010, 107:10737-10742.
8. Tseng C.L., Wu S.Y., Wang W.H., Peng C.L., Lin F.H., Lin C.C., et al. Targeting efficiency and biodistribution of biotinylated-EGF-conjugated gelatin nanoparticles administered via aerosol delivery in nude mice with lung cancer. Biomaterials 2008, 29:3014-3022.
9. Patton J.S., Byron P.R. Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov 2007, 6:67-74.
10. Youn Y.S., Lee K.C., Bae Y.H., Na K., Lee E.S. Advanced pulmonary delivery of peptides or proteins using polymeric particles. Delivery technologies for biopharmaceuticals: peptides, proteins, nucleic acids, and vaccines 2009, 228-244. WILEY. L. Jorgensen, H.M. Nielsen (Eds.).
11. Kim H., Park H., Lee J., Kim T.H., Lee E.S., Oh K.T., et al. Highly porous large poly(lactic-co-glycolic acid) microspheres adsorbed with palmityl-acylated exendin-4 as a long-acting inhalation system for treating diabetes. Biomaterials 2011, 32:1685-1693.
12. Kim H., Lee J., Kim T.H., Lee E.S., Oh K.T., Lee D.H., et al. Albumin-coated porous hollow poly(lactic-co-glycolic acid) microparticles bound with palmityl-acylated exendin-4 as a long-acting inhalation delivery system for the treatment of diabetes. Pharm Res 2011, 28:2008-2019.
13. Kwon M.J., Bae J.H., Kim J.J., Na K., Lee E.S. Long acting porous microparticles for pulmonary drug delivery. Int J Pharm 2007, 333:5-9.
14. Kim T.K., Yoon J.J., Lee D.S., Park T.G. Gas foamed open porous biodegradable polymeric microspheres. Biomaterials 2006, 27:152-159.
15. Edwards D.A., Hanes J., Caponetti G., Hrkach J., Ben-Jebria A., Eskew M.L., et al. Large porous particles for pulmonary drug delivery. Science 1997, 276:1868-1871.
16. Edwards D.A., Ben-Jebria A., Langer R. Recent advances in pulmonary drug delivery using large, porous inhaled particles. J Appl Physiol 1998, 85:379-385.
17. Vanbever R., Mintzes J.D., Wang J., Nice J., Chen D., Batycky R., et al. Formulation and physical characterization of large porous particles for inhalation. Pharm Res 1999, 16:1735-1742.
18. Yang Y., Bajaj N., Xu P., Ohn K., Tsifansky M.D., Yeo Y. Development of highly porous large PLGA microparticles for pulmonary drug delivery. Biomaterials 2009, 30:1947-1953.
19. Ungaro F., De Rosa G., Miro A., Quaglia F., La Rotonda M.I. Cyclodextrins in the production of large porous particles: development of dry powders for the sustained release of insulin to the lungs. Eur J Pharm Sci 2006, 28:423-432.
20. Bae S., Ma K., Kim T.H., Lee E.S., Oh K.T., Park E.S., et al. Doxorubicin-loaded human serum albumin nanoparticles surface-modified with TNF-related apoptosis-inducing ligand and transferrin for targeting multiple tumor types. Biomaterials 2012, 33:1536-1546.
21. Jiang H.H., Kim T.H., Lee S., Chen X., Youn Y.S., Lee K.C. PEGylated TNF-related apoptosis-inducing ligand (TRAIL) for effective tumor combination therapy. Biomaterials 2011, 32:8529-8537.
22. Welch H.G., Schwartz L.M., Woloshin S. Are increasing 5-year survival rates evidence of success against cancer?. JAMA 2000, 283:2975-2978.
23. Roa W.H., Azarmi S., Al-Hallak M.H., Finlay W.H., Magliocco A.M., Löbenberg R. Inhalable nanoparticles, a non-invasive approach to treat lung cancer in a mouse model. J Control Release 2011, 150:49-55.
24. Kim H.K., Chung H.J., Park T.G. Biodegradable polymeric microspheres with " open/closed" pores for sustained release of human growth hormone. J Control Release 2006, 112:167-174.
25. Bae S.E., Son J.S., Park K., Han D.K. Fabrication of covered porous PLGA microspheres using hydrogen peroxide for controlled drug delivery and regenerative medicine. J Control Release 2009, 133:37-43.
26. Veronese F.M., Schiavon O., Pasut G., Mendichi R., Andersson L., Tsirk A., et al. PEG-doxorubicin conjugates: influence of polymer structure on drug release, in vitro cytotoxicity, biodistribution, and antitumor activity. Bioconjug Chem 2005, 16:775-784.
27. Co N.N., Tsang W.P., Wong T.W., Cheung H.H., Tsang T.Y., Kong S.K., et al. Oncogene AF1q enhances doxorubicin-induced apoptosis through BAD-mediated mitochondrial apoptotic pathway. Mol Cancer Ther 2008, 7:3160-3168.
28. Li L., Lu Q., Shen Y., Hu X. Schisandrin B enhances doxorubicin-induced apoptosis of cancer cells but not normal cells. Biochem Pharmacol 2006, 71:584-595.
29. Xia M., Knezevic D., Vassilev L.T. p21 does not protect cancer cells from apoptosis induced by nongenotoxic p53 activation. Oncogene 2011, 30:346-355.
30. Shive M.S., Anderson J.M. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev 1997, 28:5-24.
31. Baker G.L., Gupta A., Clark M.L., Valenzuela B.R., Staska L.M., Harbo S.J., et al. Inhalation toxicity and lung toxicokinetics of C60 fullerene nanoparticles and microparticles. Toxicol Sci 2008, 101:122-131.